Bio-Rad Announces that Through its Exact Diagnostics Product Line, the Company has Launched a SARS CoV-2 Standard for Coronavirus (COVID-19) Testing
Bio-Rad Laboratories, Inc. Class A (BIO)
Last bio-rad laboratories, inc. class a earnings: 2/13 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
bio-rad.com/en-us/corporate/investor-relations
Company Research
Source: Business Wire
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that through its Exact Diagnostics product line Bio-Rad has launched a SARS CoV-2 Standard to support laboratory assay validation of coronavirus (COVID-19) testing. Bio-Rad is providing the SARS CoV-2 Standard to help labs validate their COVID-19 assay results and accelerate access to testing.The Clinical Laboratory Improvement Amendments (CLIA) federal regulatory standards require clinical laboratories to establish and document their own performance specifications for laboratory-developed tests to ensure accurate and precise results prior to the implementation of the test. The SARS CoV-2 Standard contains synthetic COVID-19 RNA transcripts and human genomic DNA, allowing laboratories to test the entire process of a molecular assay including extraction, amplification, and detection of the virus.“In a public h
Show less
Read more
Impact Snapshot
Event Time:
BIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIO alerts
High impacting Bio-Rad Laboratories, Inc. Class A news events
Weekly update
A roundup of the hottest topics
BIO
News
- Bioprocess Validation Market to hit USD 1.03 billion by 2032, says Global Market Insights Inc. [Yahoo! Finance]Yahoo! Finance
- Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $369.00 to $481.00. They now have an "outperform" rating on the stock.MarketBeat
- Microbiome Diagnostics Market Revenue Projections to 2034 by Product, Technology, Sample, Application, End-user, and by Region [Yahoo! Finance]Yahoo! Finance
- Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts, Strategies, Trends, Forecasts with Executive Guides [Yahoo! Finance]Yahoo! Finance
BIO
Earnings
- 10/30/24 - Beat
BIO
Sec Filings
- 12/20/24 - Form SCHEDULE
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- BIO's page on the SEC website